Please click here to get more information. (Symbol: 6541)

• Sep 4th, 2024 Tanvex Appoints Biopharma Industry Veteran Stephen Lam as CEO
• Aug 27st, 2024 Tanvex Forging Strategic Alliance with Bora Pharmaceuticals
• Aug 1st, 2024 FDA accepts TX05 BLA resubmission
• Jul 8th, 2024 TX05 BLA resubmisson
• Jul 1st, 2024 Tanvex received BLA approval from FDA
• Dec 29, 2023 Tanvex BioPharma Elects Henry Chen as Chairman
• Oct 17, 2023 Tanvex CDMO Launch Empowers Advancements in Novel Biologics and Biosimilars
• June 28, 2023 Tanvex BioPharma Accelerates CDMO Layout to Expand Business Opportunities
• May 16, 2023 Tanvex BioPharma Enters Exclusive Distribution Agreement for Nypozi (filgrastim) in Canada
• Feb 9, 2023 Tanvex Reaches Settlement and License Agreement with Genentech
• Oct 17, 2021 Tanvex received marketing authorization from Health Canada
• Oct 4, 2021 FDA Accepts TX05 BLA Filing
• Aug 3, 2021 Tanvex submits TX05 BLA to FDA
• Jun 20, 2021 Tanvex entering into service contract with OBI
• May. 21, 2021 FDA delayed inspection for TX01
• Mar 2, 2021 Tanvex has reached a Patent License Agreement with Amgen
• Feb 20, 2021 Positive top-line efficacy and safety data from global Phase III clinical trial of Tanvex trastuzumab biosimilar candidate, TX05
• Nov 27, 2020 Clinical Trial Completion of Last Patient Surgery for TX05
• Nov 22, 2020 TX01 BLA Resubmission
• Nov 17, 2020 Tanvex submits TX01 NDS responses to Health Canada
• Nov 10, 2020 US Patent Issued
• Oct 22, 2020 Clinical Trial Completion of Treatment for TX05
• Mar 19, 2020 Clinical Trial Completion of Enrollment for TX05
• Dec 17, 2019 Tanvex Settles Patent Dispute with Amgen
• Sep 25, 2019 Response from FDA for TX01
• Sep 24, 2019 Tanvex filed response to Amgen’s lawsuit
• Jul 25, 2019 Amgen files infringement lawsuit against Tanvex
• Mar 11, 2019 Canada Accepts Tanvex NDS submission for TX01
• Jan 16, 2019 Tanvex submits NDS for TX01 to Health Canada
• Dec 06, 2018 Tanvex BioPharma Attends ASHP
• Nov 28, 2018 FDA Accepts TX01 BLA Filing
• Oct 01, 2018 Tanvex BioPharma Submits its First Biologics License Application to U.S. FDA For TX-01
• Sep 19, 2018 Tanvex BioPharma to present at the YuanTa Biotech Investment Forum Asia 2018
• Sep 05, 2018 Public offering of common stock completed
• Aug 14, 2018 Tanvex Biologics Corporation (Taiwan) to expand process development capability
• Jul 26, 2018 Tanvex BioPharma USA, Inc. signed agreement in Japan
• Jul 04, 2018 Tanvex BioPharma announces proposed public offering of common stock
• May 17, 2018 Tanvex Has Been Added to the MSCI Global Small Cap Index
• Mar 20, 2018 Tanvex BioPharma to present at the 2018 BIO Asia International Conference
• Mar 12, 2018 Tanvex BioPharma to present at the 30 th Annual ROTH Conference
• Mar 1, 2018 Tanvex Name Change
• Jan 17, 2018 Tanvex BioPharma, Inc. held road show presentation
• Dec 19, 2017 TX16 Completed PK Study
• Oct 26, 2017 Tanvex BioPharma, Inc. got IPO in Taiwan
• Sep 28, 2017 TX05 Press Release
• Aug 24, 2017 TX01 Press Release
• July 20, 2017 Tanvex BioPharma, Inc. held road show presentation on July 20, 2017
• November 30, 2016 Tanvex BioPharma, Inc. has applied for primary listing on the Taiwan Stock Exchange.
• October 3, 2016 Tanvex BioPharma, Inc. Announces Initiation of Pivotal Trial of TX01 (a Proposed Biosimilar of Neupogen®)
• June 16, 2016 The 2016 Annual General Meeting of Tanvex Biopharma Inc. has passed several resolutions.
• June 14, 2016 Tanvex BioPharma, Inc. announced that the Board of Directors has approved to establish a new subsidiary in USA for its operational and business needs.
• March 28, 2016 Tanvex Biologics Corporation (Taiwan), a wholly owned subsidiary of Tanvex BioPharma, Inc. announced the result of its Board of Directors re-election.